A Cohort Study on the Association Between Serum Erythropoietin Dynamics and Prognosis in Patients with Metastatic Renal Cell Carcinoma Treated with Belzutifan

A Cohort Study on the Association Between Serum Erythropoietin Dynamics and Prognosis in Patients with Metastatic Renal Cell Carcinoma Treated with Belzutifan - A Cohort Study on the Association Between Serum Erythropoietin Dynamics and Prognosis in Patients with Metastatic Renal Cell Carcinoma Treated with Belzutifan

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059028

Enrollment

Registered

2025-10-15

Start date

2025-10-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with a pathological diagnosis of renal cell carcinoma who are receiving treatment with belzutifan Age >= 20 years Written informed consent obtained from the patient

Exclusion criteria

Exclusion criteria: Patients concurrently receiving anticancer therapy for another malignancy (except hormonal therapy for prostate cancer) Patients with severe cardiopulmonary disease or uncontrolled infections Patients deemed inappropriate for study participation by the principal investigator

Design outcomes

Primary

Measure	Time frame
Progression-Free Survival	—

Secondary

Measure	Time frame
Overall survival Time to onset of anemia Time to onset of hypoxia, based on SpO2 measurements or clinical diagnosis Occurrence and timing of treatment interruption or dose reduction due to anemia or hypoxia Incidence of adverse events	—

Countries

Japan

Contacts

Public ContactTakuto Hara

Kobe University Graduate School of Medicine Division of Urology

urokobe@med.kobe-u.ac.jp0783826155

Outcome results